Document:

Exhibit 10.25

 

ARTARA THERAPEUTICS, INC.

AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN, AS AMENDED

 

STOCK OPTION AGREEMENT

 

THIS AGREEMENT dated as of                                    ,
20    , between ArTara Therapeutics, Inc., a corporation organized under the laws of the State of Delaware
(the “Company”), and the individual identified in paragraph 1 below, currently residing at the address set out
at the end of this Agreement (the “Optionee”).

 

1.                                      Grant
of Option.  Pursuant and subject to the Company’s Amended and Restated 2014 Equity Incentive Plan, as amended (as
the same may be amended from time to time, the “Plan”), the Company grants to you, the Optionee identified in
the table below, an option (the “Option”) to purchase from the Company all or any part of a total of the number
of shares identified in the table below (the “Optioned Shares”) of the common stock, par value $0.001 per share,
in the Company (the “Stock”), at the exercise price per share set out in the table below.

 

	 	Optionee	 	 
	 	 	 	 
	 	Number of Shares	 	 
	 	 	 	 
	 	Exercise Price Per Share	 	 
	 	 	 	 
	 	Grant Date	 	 
	 	 	 	 
	 	Expiration Date(1)	 	 

 

2.                                      Character
of Option.  This Option [is/is not](2) intended to be treated as an “incentive stock option” within
the meaning of Section 422 of the Internal Revenue Code of 1986, as amended.

 

3.                                      Expiration
of Option.  This Option shall expire at 5:00 p.m. Eastern Standard Time on the Expiration Date or, if earlier, the earliest
of the dates specified in whichever of the following applies:

 

a)                                     If
the termination of your employment or other association is on account of your death or disability, the first anniversary of the
date your employment ends.

b)                                     If
the termination of your employment or other association is due to any other reason, three (3) months after your employment or other
association ends.

_______________________

(1) For ISOs not later than the day immediately
preceding the tenth anniversary of the Grant Date.  NQSOs may have a later expiration date, if the Plan allows.  But
as a general matter, NQSOs will also have an expiration date of not later than the day immediately preceding the tenth anniversary
of the Grant Date.

(2) Either “is” or “is not”,
as the Committee has determined.

 

4.                                      Exercise
of Option.

 

a)                                     You
may exercise this Option as to the number of Optioned Shares which have vested (the “Vested Shares”) under this
paragraph 4, in full or in part and at any time prior to the Expiration Date.  However, during any period that this Option
remains outstanding after your employment or other association with the Company and its Affiliates ends, you may exercise it only
to the extent of any remaining Vested Shares determined as of immediately prior to the end of your employment or other association. 
The procedure for exercising this Option is described in Section 7.1(e) of the Plan.

 

b)                                     [Time-based
vesting: That number of Optioned Shares specified in the table below shall become Vested Shares on the date set opposite
such number in the table below:]

 

     

     

    

	Number of Shares

in Each Installment	 	Initial Vesting Date

for Shares in Installment
	 	 	 
	 	 	 
	 	 	 

c)                                      [Performance-based
vesting]

d)                                     [Other
vesting, e.g., Change of Control]

 

5.                                      Transfer
of Option.  Except if and to the extent otherwise provided under the Plan, you may not transfer this Option except by
will or the laws of descent and distribution, and, during your lifetime, only you may exercise this Option.

 

6.                                      Incorporation
of Plan Terms.  This Option is granted subject to all of the applicable terms and provisions of the Plan, including but
not limited to the limitations on the Company’s obligation to deliver Optioned Shares upon exercise set forth in Section
10 (Settlement of Awards).

 

7.                                      Tax
Consequences.  The Company makes no representation or warranty as to the tax treatment to you of your receipt or exercise
of this Option or upon your sale or other disposition of the Optioned Shares.  You should rely on your own tax advisors for
such advice.

 

8.                                      Acknowledgements. 
You acknowledge that you have reviewed and understand the Plan and this Agreement in their entirety, and have had an opportunity
to obtain the advice of counsel prior to executing this Agreement.  You hereby agree to accept as binding, conclusive and
final all decisions or interpretations of the Committee upon any questions arising under the Plan or this Agreement.

 

9.                                      Further
Assurances.  The parties agree to execute such further instruments and to take such action as may reasonably be necessary
to carry out the intent of this Agreement.

 

[10.                      Community
Property.  Without prejudice to the actual rights of the spouses as between each other, for all purposes of this Agreement,
you shall be treated as agent and attorney-in-fact for that interest held or claimed by your spouse with respect to this Option
and any Optioned Shares and the parties hereto shall act in all matters as if the Optionee was the sole owner of this Option and
(following exercise) any such Optioned Shares.  This appointment is coupled with an interest and is irrevocable.](3)

 

11.                               Miscellaneous. 
This Agreement shall be construed and enforced in accordance with the laws of the Commonwealth of Massachusetts without regard
to the conflict of laws principles thereof and shall be binding upon and inure to the benefit of any successor or assign of the
Company and any executor, administrator, trustee, guardian, or other legal representative of you.  Capitalized terms used
but not defined herein shall have the meaning assigned under the Plan.  This Agreement may be executed in one or more counterparts
all of which together shall constitute but one instrument. In making proof of this Agreement it shall not be necessary to produce
or account for more than one such counterpart.

 

[Signature page follows]

 

_____________________ 

(3) Consider for inclusion for grants to California
residents (and residents of other states with community property rules).

 

     

     

    

IN WITNESS WHEREOF, the parties have
executed this Agreement as of the date first above written.

 

	ARTARA THERAPEUTICS, INC.	 
	 	 
	 	 	 	 
	By:	 	 	 
	 	 	 	Signature of Optionee
	 	 	 	 
	Title:	 	 	 
	 	 	 	Optionee’s Address:
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

 

 

 

 

     

     

    

ARTARA THERAPEUTICS, INC.

AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN, AS AMENDED

 

OPTION EXERCISE FORM

 

ArTara Therapeutics, Inc.

1 Little West 12th Street

New York, NY 10014

 

Attention:       Chief
Financial Officer

 

Dear Sir:

 

In accordance with and subject to the terms
and conditions of the ArTara Therapeutics, Inc. Amended and Restated 2014 Equity Incentive Plan, as amended, I hereby elect to
exercise my option granted under the agreement dated                               ,
to purchase                                           (               )
shares of the common stock, par value $0.001 per share, in ArTara Therapeutics, Inc. (the “Company”).

 

Enclosed herewith is payment to the Company
in the amount of                                                          Dollars
($                   ) in
full payment of the option price for said shares.  [To be revised as necessary for non-cash payment of exercise price.]

 

	 	Sincerely yours,
	 	 
	 	 
	 	 
	 	Name:

 

     

     

    

Executive/Employee Form

 

ArTara Therapeutics,
Inc.

Restricted Stock Unit Award Grant Notice

(Amended and Restated 2014 Equity Incentive Plan)

ArTaraTherapeutics, Inc. (the “Company”),
pursuant to its Amended and Restated 2014 Equity Incentive Plan (the “Plan”), hereby grants to Participant
a Restricted Stock Unit Award (the “Award”) under the Plan for the number of restricted stock units (the
“RSUs”) set forth below. This Award is subject to all of the terms and conditions set forth in this Restricted
Stock Unit Award Grant Notice (the “Grant Notice”) and in the Restricted Stock Unit Award Agreement (the
“Agreement”) and the Plan, all of which are incorporated herein in their entirety. Capitalized terms
not otherwise defined herein shall have the meanings set forth in the Plan or the Agreement.

	Participant:	 
	Date
    of Grant:	 
	Vesting
    Commencement Date:	 
	Number
    of RSUs Subject to Award:	 

Vesting Schedule: This Award
will vest as follows: [____________].

 

Issuance Schedule:Subject
to adjustment as provided under the Plan, one share of Stock will be issued for each RSU that vests at the time set forth in Section
6 of the Agreement.

Additional Terms/Acknowledgements: By accepting the Award,
you acknowledge receipt of, and understand and agree to, this Grant Notice, the and the Plan. You also acknowledge receipt of the
Prospectus for the Plan. You further acknowledge that as of the Date of Grant, this Grant Notice, the Agreement and the Plan set
forth the entire understanding between you and the Company regarding the Award and supersedes all prior oral and written agreements
on that subject, with the exception, if applicable, of (i) any compensation recovery policy that is adopted by the Company or is
otherwise required by applicable law, (ii) any written employment, offer letter or severance agreement, or any written severance
plan or policy specifying the terms that should govern this Award, or (iii) any separate election you enter into with the Company’s
written approval which is also applicable to the Award.

	ArTara Therapeutics, Inc.	 	Participant
	 	 	 	 	 
	By: 	 	 	 	 
	 	Signature	 	Signature
	 	 	 	 	 
	Title:	 	 	Date:	 
	Date:	 	 	 	 

     

     

    

ArTara Therapeutics, Inc.

Amended and Restated

2014 Equity Incentive
Plan

Restricted Stock Unit
Award Agreement

Pursuant to your Restricted Stock Unit Award
Grant Notice (the “Grant Notice”), this Restricted Stock Unit Award Agreement (the “Agreement”)
and in consideration of your services, ArTara Therapeutics, Inc. (the “Company”) has awarded you a Restricted
Stock Unit Award (the “Award”) under its Amended and Restated 2014 Equity Incentive Plan (the “Plan”)
for the number of restricted stock units (the “Restricted Stock Units”) set forth in the Grant Notice.
This Award is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”).
Capitalized terms not explicitly defined in this Agreement but defined in the Plan or the Grant Notice will have the same definitions
as in the Plan or the Grant Notice. The details of your Award, in addition to those set forth in the Grant Notice and the Plan,
are as follows.

1.                  
Grant of the Award. This Award represents your right to be issued on a future
date (as set forth in Section 6) one share of Stock for each Restricted Stock Unit subject to this Award that vests in accordance
with the Grant Notice and this Agreement.

2.                  
Vesting. The Award will vest, if at all, in accordance with the vesting schedule
set forth in the Grant Notice, provided that vesting will cease upon the termination of your continuous service with the Company.
Upon such termination of your continuous service with the Company, you will forfeit (at no cost to the Company) any Restricted
Stock Units subject to this Award that have not vested as of the date of such termination and you will have no further right, title
or interest in such Restricted Stock Units or this Award.

3.                  
Number of Restricted Stock Units and Shares of Stock.

(a)               
The number of Restricted Stock Units subject to this Award, as set forth in the Grant Notice, will be adjusted for such events
described in Sections 8.1 and 8.2 of the Plan, if any.

(b)              
Any additional Restricted Stock Units and any shares of Stock, cash or other property that become subject to this Award pursuant
to this Section 3 will be subject, in a manner determined by the Committee, to the same forfeiture restrictions, restrictions on
transferability, and time and manner of issuance as applicable to the other Restricted Stock Units subject to this Award to which
they relate.

(c)               
No fractional shares or rights for fractional shares of Stock will be created pursuant to this Section 3. Any fractional shares
that may be created by the adjustments referred to in this Section 3 will be rounded down to the nearest whole share.

4.                  
Securities Law Compliance. You will not be issued any shares of Stock in respect
of this Award unless either (i) such shares are registered under the Securities Act of 1933, as amended (the “Securities
Act”), or (ii) the Company has determined that such issuance would be exempt from the registration requirements of
the Securities Act. This Award also must comply with all other applicable laws and regulations governing this Award, and you will
not receive any shares of Stock in respect of this Award if the Company determines that such receipt would not be in material compliance
with such laws and regulations.

    	 	1.	 

     

    

5.                  
Transferability. Except as otherwise provided in this Section 5, this Award is
not transferable, except by will or by the laws of descent and distribution, and prior to the time that shares of Stock in respect
of this Award have been issued to you, you may not transfer, pledge, sell or otherwise dispose of any portion of the Restricted
Stock Units or the shares of Stock in respect of this Award. For example, you may not use any shares of Stock that may be issued
in respect of this Award as security for a loan, nor may you transfer, pledge, sell or otherwise dispose of such shares. This restriction
on transfer will lapse upon issuance to you of the shares of Stock in respect of this Award.

6.                  
Date of Issuance. 

(a)               
If the Award is exempt from application of Section 409A of the Code and any state law of similar effect (collectively “Section
409A”), the Company will deliver to you a number of shares of the Company’s Stock equal to the number of vested
Restricted Stock Units subject to your Award, including any additional Restricted Stock Units received pursuant to Section 3 above
that relate to those vested Restricted Stock Units on the applicable vesting date (the “Original Issuance Date”).
However, if the Original Issuance Date falls on a date that is not a business day, such delivery date shall instead fall on the
next following business day. Notwithstanding the foregoing, if (i) the Original Issuance Date does not occur (1) during
an “open window period” applicable to you, as determined by the Company in accordance with the Company’s then-effective
policy or policies on trading in Company securities or (2) on a date when you are otherwise permitted to sell shares of Stock
on the open market; and (ii) the Company elects, prior to the Original Issuance Date, (x) not to satisfy the Withholding
Obligation (as defined in Section 10(a) hereof) by withholding shares of Stock from the shares otherwise due, on the Original
Issuance Date, to you under this Award pursuant to Section 10 hereof, (y) not to permit you to then effect a “same
day sale” to cover the Withholding Obligation pursuant to Section 10 hereof, and (z) not to permit you to satisfy the Withholding
Obligation in cash, then such shares shall not be delivered on such Original Issuance Date and shall instead be delivered on the
first business day of the next occurring open window period applicable to you or the next business day when you are not prohibited
from selling shares of the Company’s Stock on the open market, as applicable (and regardless of whether there has been a
termination of your continuous service with the Company before such time), but in no event later than the 15th day of the third
calendar month of the calendar year following the calendar year in which the Restricted Stock Units vest. Delivery of the shares
pursuant to the provisions of this Section 6(a) is intended to comply with the requirements for the short-term deferral exemption
available under Treasury Regulations Section 1.409A-1(b)(4) and shall be construed and administered in such manner. The form of
such delivery of the shares (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by
the Company.

(b)              
The provisions of this Section 6(b) are intended to apply if the Award is subject to Section 409A because of the terms of a
severance arrangement or other agreement between you and the Company, if any, that provide for acceleration of vesting of the Award
upon your separation from service (as such term is defined in Section 409A(a)(2)(A)(i) of the Code (“Separation from
Service”) and such severance benefit does not satisfy the requirements for an exemption from application of Section
409A provided under Treasury Regulations Section 1.409A-1(b)(4) or 1.409A-1(b)(9) (“Non-Exempt Severance Arrangement”).
If the Award is subject to and not exempt from application of Section 409A due to application of a Non-Exempt Severance Arrangement,
the following provisions in this Section 6(b) shall supersede anything to the contrary in Section 6(a).

(i)                
If the Award vests in the ordinary course before your termination of continuous service
with the Company in accordance with the vesting schedule set forth in the Grant Notice, without accelerating vesting under the
terms of a Non-Exempt Severance Arrangement, in no event will the shares to be issued in respect of your Award be issued any later
than the later of: (A) December 31st of the calendar year that includes the applicable vesting date and (B) the 60th
day that follows the applicable vesting date. 

    	 	2.	 

     

    

(ii)             
If vesting of the Award accelerates under the terms of a Non-Exempt Severance Arrangement
in connection with your Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant
of the Award and, therefore, are part of the terms of the Award as of the date of grant, then the shares will be earlier issued
in respect of your Award upon your Separation from Service in accordance with the terms of the Non-Exempt Severance Arrangement,
but in no event later than the 60th day that follows the date of your Separation from Service. However, if at the time
the shares would otherwise be issued you are subject to the distribution limitations contained in Section 409A applicable to “specified
employees,” as defined in Section 409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six
months and one day following the date of your Separation from Service, or, if earlier, the date of your death that occurs within
such six-month period.

(iii)           
If either (A) vesting of the Award accelerates under the terms of a Non-Exempt Severance
Arrangement in connection with your Separation from Service, and such vesting acceleration provisions were not in effect as of
the date of grant of the Award and, therefore, are not a part of the terms of the Award on the date of grant, or (B) vesting accelerates
pursuant to Section 2(b) or Section 9 of the Plan, then such acceleration of vesting of the Award shall not accelerate the issuance
date of the shares (or any substitute property), but the shares (or substitute property) shall instead be issued on the same schedule
as set forth in the Grant Notice as if they had vested in the ordinary course before your termination of continuous service with
the Company, notwithstanding the vesting acceleration of the Award. Such issuance schedule is intended to satisfy the requirements
of payment on a specified date or pursuant to a fixed schedule, as provided under Treasury Regulations Section 1.409A-3(a)(4).

(c)               
Notwithstanding anything to the contrary set forth herein, the Company explicitly reserves the right to earlier issue the shares
in respect of any Award to the extent permitted and in compliance with the requirements of Section 409A, including pursuant to
any of the exemptions available in Treasury Regulations Section 1.409A-3(j)(4)(ix).

(d)              
The provisions in this Agreement for delivery of the shares in respect of the Award are intended either to comply with the
requirements of Section 409A or to provide a basis for exemption from such requirements so that the delivery of the shares will
not trigger the additional tax imposed under Section 409A, and any ambiguities herein will be so interpreted.

7.                  
Dividends. You will receive no benefit or adjustment to this Award with respect
to any cash dividend, stock dividend or other distribution except as provided in the Plan with respect to adjustments pursuant
to Sections 8.1 and 8.2.

8.                  
Restrictive Legends. The shares of Stock issued in respect of this Award will
be endorsed with appropriate legends, if any, as determined by the Company.

9.                  
Award Not a Service Contract.

(a)               
Your continuous service with the Company or an Affiliate is not for any specified term and may be terminated by you or by the
Company or an Affiliate at any time, for any reason, with or without cause and with or without notice.  Nothing in this Agreement
(including, but not limited to, the vesting of your Award pursuant to the schedule set forth in Section 2 in this Agreement or
the issuance of the shares subject to your Award), the Plan or any covenant of good faith and fair dealing that may be found implicit
in this Agreement or the Plan will:  (i) confer upon you any right to continue in the employ of, or affiliation with, the
Company or an Affiliate; (ii) constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature
of future positions, future work assignments, future compensation or any other term or condition of employment or affiliation;
(iii) confer any right or benefit under this Agreement or the Plan unless such right or benefit has specifically accrued under
the terms of this Agreement or Plan; or (iv) deprive the Company or an Affiliate of the right to terminate you at will and without
regard to any future vesting opportunity that you may have.

    	 	3.	 

     

    

(b)              
By accepting this Award, you acknowledge and agree that the right to continue vesting in the Award is earned only through continuous
service with the Company (not through the act of being hired, being granted this Award or any other award or benefit) and that
the Company has the right to reorganize, sell, spin-out or otherwise restructure one or more of its businesses or Affiliates at
any time or from time to time, as it deems appropriate (a “reorganization”).  You further acknowledge
and agree that such a reorganization could result in the termination of your continuous service with the Company, or the termination
of Affiliate status of your employer and the loss of benefits available to you under this Agreement, including but not limited
to, the termination of the right to continue vesting in the Award. You further acknowledge and agree that this Agreement, the Plan,
the transactions contemplated hereunder and the vesting schedule set forth in this Agreement or any covenant of good faith and
fair dealing that may be found implicit in any of them do not constitute an express or implied promise of continued engagement
as an employee, director or consultant for the term of this Agreement, for any period, or at all, and will not interfere in any
way with your right or the Company’s or an Affiliate’s right to terminate your continuous service with the Company
at any time, with or without cause and with or without notice.

10.              
Withholding Obligations.

(a)               
On or before the time you receive a distribution of Stock pursuant to your Award, or at any time thereafter as requested by
the Company, you hereby authorize any required withholding from the Stock issuable to you and/or otherwise agree to make adequate
provision in cash for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company
or any Affiliate which arise in connection with your Award (the “Withholding Obligation”).

(b)              
The Company may, in its sole discretion, satisfy all or any portion of the Withholding Taxes obligation relating to your Award
by any of the following means or by a combination of such means:

(i)                
 withholding from any compensation otherwise payable to you by the Company; 

(ii)             
causing you to tender a cash payment; 

(iii)           
permitting you to enter into a “same day sale” commitment with a broker-dealer
that is a member of the Financial Industry Regulatory Authority (a “FINRA Dealer”) whereby you irrevocably
elect to sell a portion of the shares to be delivered in connection with your Award to satisfy the Withholding Taxes and whereby
the FINRA Dealer irrevocably commits to forward the proceeds necessary to satisfy the Withholding Taxes directly to the Company
and/or its Affiliates; or 

(iv)            
withholding shares of Stock from the shares of Stock issued or otherwise issuable to you
in connection with the Award with a Fair Market Value (measured as of the date shares of Stock are issued pursuant to Section 6)
equal to the amount of the Withholding Obligation; provided, however, that the number of such shares of Stock so withheld
shall not exceed the amount necessary to satisfy the Company’s or Affiliate’s tax withholding obligations as permitted
while still avoiding classification of the Award as a liability for financial accounting purposes and provided, further, that to
the extent necessary to qualify for an exemption from application of Section 16(b) of the Securities Exchange Act of 1934, as amended,
if applicable, such share withholding procedure will be subject to the express prior approval of the Board or the Committee.

    	 	4.	 

     

    

(c)               
Unless the Withholding Obligation of the Company and/or any Affiliate are satisfied, the Company shall have no obligation to
deliver to you any Stock.

(d)              
In the event the Withholding Obligation of the Company arises prior to the delivery to you of Stock or it is determined after
the delivery of Stock to you that the amount of the Withholding Obligation was greater than the amount withheld by the Company,
you agree to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount.

11.              
Tax Consequences. The Company has no duty or obligation to minimize the tax consequences
to you of this Award and will not be liable to you for any adverse tax consequences to you arising in connection with this Award.
You are hereby advised to consult with your own personal tax, financial and/or legal advisors regarding the tax consequences of
this Award and by accepting this Award, you have agreed that you have done so or knowingly and voluntarily declined to do so.

12.              
Unsecured Obligation. Your Award is unfunded, and as a holder of a vested Award,
you will be considered an unsecured creditor of the Company with respect to the Company’s obligation, if any, to issue shares
pursuant to this Agreement. You will not have voting or any other rights as a stockholder of the Company with respect to the shares
to be issued pursuant to this Agreement until such shares are issued to you. Upon such issuance, you will obtain full voting and
other rights as a stockholder of the Company. Nothing contained in this Agreement, and no action taken pursuant to its provisions,
will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other
person.

13.              
Other Documents. You hereby acknowledge receipt or the right to receive a document
providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus.
In addition, you acknowledge receipt of the Company’s policy permitting certain individuals to sell shares only during certain
“window” periods and the Company’s insider trading policy, in effect from time to time and understand that this
policy applies to shares received under this Award.

14.              
Notices; Electronic Delivery. Any
notices provided for in your Award or the Plan will be given in writing and will be deemed effectively given upon receipt or, in
the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed
to you at the last address you provided to the Company. Notwithstanding the foregoing, the Company may, in its sole discretion,
decide to deliver any documents and transmit or require you to transmit notices related to participation in the Plan and this Award
by electronic means. You hereby consent to receive such documents and notices, and to give such notices, by electronic delivery
and to participate in the Plan through the on-line or electronic system established and maintained by the Company or another third
party designated by the Company from time to time.

15.              
Miscellaneous.

(a)               
The rights and obligations of the Company under your Award will be transferable to any one or more persons or entities, and
all covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company’s successors and assigns.
Your rights and obligations under your Award may only be assigned with the prior written consent of the Company.

(b)              
You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of
the Company to carry out the purposes or intent of your Award.

    	 	5.	 

     

    

(c)               
You acknowledge and agree that you have reviewed your Award in its entirety, have had an opportunity to obtain the advice of
counsel prior to executing and accepting your Award, and fully understand all provisions of your Award.

(d)              
This Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies
or national securities exchanges as may be required.

(e)               
All obligations of the Company under the Plan and this Agreement will be binding on any successor to the Company, whether the
existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially
all of the business and/or assets of the Company.

16.              
Governing Plan Document. This Award is subject to all the provisions of the Plan,
the provisions of which are hereby made a part of this Award, and is further subject to all interpretations, amendments, rules
and regulations which may from time to time be promulgated and adopted pursuant to the Plan. Except as otherwise expressly provided
in the Grant Notice or this Agreement, in the event of any conflict between the terms in the Grant Notice or this Agreement and
the terms of the Plan, the terms of the Plan will control. In addition, this Award (and any shares issued under this Award) is
subject to recoupment in accordance with the Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing
regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable
law.

17.              
Effect on Other Employee Benefit Plans. The value of this Award will not be included
as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan
sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its
rights to amend, modify, or terminate any of the Company’s or any Affiliate’s employee benefit plans.

18.              
Stockholder Rights.  You will not have voting or any other rights as a stockholder
of the Company with respect to the shares of Stock to be issued pursuant to this Award until such shares are issued to you. Upon
such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this Agreement,
and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship
between you and the Company, any Affiliate or any other person.

19.              
Severability. If any part of this Agreement or the Plan is declared by any court
or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Agreement
or the Plan not declared to be unlawful or invalid. Any Section of this Agreement (or part of such a Section) so declared to be
unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of
a Section to the fullest extent possible while remaining lawful and valid.

20.              
Choice of Law. The interpretation, performance and enforcement of this Agreement
will be governed by the law of the state of Delaware without regard to such state’s conflicts of laws rules.

21.              
Amendment. This Agreement may not be modified, amended or terminated except by
an instrument in writing, signed by you and by a duly authorized representative of the Company. Notwithstanding the foregoing,
this Agreement may be amended solely by the Committee by a writing which specifically states that it is amending this Agreement,
so long as a copy of such amendment is delivered to you, and provided that no such amendment materially adversely affects your
rights hereunder may be made without your written consent. Without limiting the foregoing, the Committee reserves the right to
change, by written notice to you, the provisions of this Agreement in any way it may deem necessary or advisable to carry out the
purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial
decision, provided that any such change shall be applicable only to rights relating to that portion of the Award which is then
subject to restrictions as provided herein.

    	 	6.	 

     

    

Non-Employee Director Form

ArTara Therapeutics,
Inc.

Deferred Restricted Stock Unit Award Grant Notice

(Amended and Restated 2014 Equity Incentive Plan)

ArTaraTherapeutics, Inc. (the “Company”),
pursuant to its Amended and Restated 2014 Equity Incentive Plan (the “Plan”), hereby grants to Participant
a Deferred Restricted Stock Unit Award (the “Award”) under the Plan for the number of Restricted Stock
Units (“RSUs”) set forth below. This Award is subject to all of the terms and conditions set forth in
this Deferred Restricted Stock Unit Award Grant Notice (the “Grant Notice”) and in the Restricted Stock
Unit Award Agreement (the “Agreement”) and the Plan, all of which are incorporated herein in their entirety.
Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or the Agreement.

	Participant:	 	 
	Date of Grant:	 	 
	Vesting Commencement Date:	 	 
	Number of RSUs Subject to Award:	 	 
	 	 	 

Vesting Schedule: This Award
will vest as follows: [________]

 

Issuance Schedule:Except
as provided in Section 6 of the Agreement, subject to adjustment as provided under the Plan, the Company will issue and deliver
one share of Stock for each RSU that has vested under this Award on the earliest to occur of the following (such date, the “Settlement
Date”):

		·	[_______], 20[___];

		·	The date of the Participant’s “separation from service” (as defined under Treasury
Regulation Section 1.409A-1(h), without regard to any alternative definitions therein, a “Separation from Service”)
as a director, unless the Participant is a “Specified Employee” (as defined under Treasury Regulation Section 1.409A-1(i))
as of the date of the Separation from Service, in which case issuance will occur on the earlier of (i) the date of the Participant’s
death and (ii) the date that is 6 months and one day after the Separation from Service (as further described and interpreted under
Section 20 of the Agreement); and

		·	A 409A Change of Control (as defined below).

409A Change in 

		Control:	A “409A Change in Control” will mean a transaction or series of transactions
that results in a Change of Control of the Company that also constitutes a “change in the ownership or effective control
of” the Company or “a change in the ownership of a substantial portion of the assets of” the Company as determined
under Treasury Regulation Section 1.409A-3(i)(5) (without regard to any alternative definition thereunder).

     

     

    

Additional Terms/Acknowledgements: By accepting the Award,
you acknowledge receipt of, and understand and agree to, this Grant Notice, the and the Plan. You also acknowledge receipt of
the Prospectus for the Plan. You further acknowledge that as of the Date of Grant, this Grant Notice, the Agreement and the Plan
set forth the entire understanding between you and the Company regarding the Award and supersedes all prior oral and written agreements
on that subject, with the exception, if applicable, of (i) any compensation recovery policy that is adopted by the Company or
is otherwise required by applicable law, (ii) any written employment, offer letter or severance agreement, or any written severance
plan or policy specifying the terms that should govern this Award, or (iii) any separate election you enter into with the Company’s
written approval which is also applicable to the Award:

	ArTara Therapeutics, Inc.	 	Participant:
	 	 	 	 	 
	By: 	 	 	 	 
	 	Signature	 	Signature
	Title: 	 	 	Date: 	 
	Date:	 	 	 	 

		Attachments:	Deferred Restricted Stock Unit Agreement

 

     

     

    

ArTara Therapeutics, Inc.

Amended and Restated

2014 Equity Incentive
Plan

Deferred Restricted
Stock Unit Award Agreement

Pursuant to your Restricted Stock Unit Award
Grant Notice (the “Grant Notice”), this Restricted Stock Unit Award Agreement (the “Agreement”)
and in consideration of your services, ArTara Therapeutics, Inc. (the “Company”) has awarded you a Restricted
Stock Unit Award (the “Award”) under its Amended and Restated 2014 Equity Incentive Plan (the “Plan”)
for the number of restricted stock units (the “Restricted Stock Units”) set forth in the Grant Notice.
This Award is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”).
Capitalized terms not explicitly defined in this Agreement but defined in the Plan or the Grant Notice will have the same definitions
as in the Plan or the Grant Notice. The details of your Award, in addition to those set forth in the Grant Notice and the Plan,
are as follows.

1.                  
Grant of the Award. This Award represents your right to be issued on a future
date (as set forth in Section 6) one share of Stock for each Restricted Stock Unit subject to this Award that vests in accordance
with the Grant Notice and this Agreement.

2.                  
Vesting. The Award will vest, if at all, in accordance with the vesting schedule
set forth in the Grant Notice, provided that vesting will cease upon the termination of your continuous service with the Company.
Upon such termination of your continuous service with the Company, you will forfeit (at no cost to the Company) any Restricted
Stock Units subject to this Award that have not vested as of the date of such termination and you will have no further right, title
or interest in such Restricted Stock Units or this Award.

3.                  
Number of Restricted Stock Units and Shares of Stock.

(a)               
The number of Restricted Stock Units subject to this Award, as set forth in the Grant Notice, will be adjusted for such events
described in Sections 8.1 and 8.2 of the Plan, if any.

(b)              
Any additional Restricted Stock Units and any shares of Stock, cash or other property that become subject to this Award pursuant
to this Section 3 will be subject, in a manner determined by the Committee, to the same forfeiture restrictions, restrictions on
transferability, and time and manner of issuance as applicable to the other Restricted Stock Units subject to this Award to which
they relate.

(c)               
No fractional shares or rights for fractional shares of Stock will be created pursuant to this Section 3. Any fractional shares
that may be created by the adjustments referred to in this Section 3 will be rounded down to the nearest whole share.

4.                  
Securities Law Compliance. You will not be issued any shares of Stock in respect
of this Award unless either (i) such shares are registered under the Securities Act of 1933, as amended (the “Securities
Act”), or (ii) the Company has determined that such issuance would be exempt from the registration requirements of
the Securities Act. This Award also must comply with all other applicable laws and regulations governing this Award, and you will
not receive any shares of Stock in respect of this Award if the Company determines that such receipt would not be in material compliance
with such laws and regulations.

    	 	1.	 

     

    

5.                  
Transferability. Except as otherwise provided in this Section 5, this Award is
not transferable, except by will or by the laws of descent and distribution, and prior to the time that shares of Stock in respect
of this Award have been issued to you, you may not transfer, pledge, sell or otherwise dispose of any portion of the Restricted
Stock Units or the shares of Stock in respect of this Award. For example, you may not use any shares of Stock that may be issued
in respect of this Award as security for a loan, nor may you transfer, pledge, sell or otherwise dispose of such shares. This restriction
on transfer will lapse upon issuance to you of the shares of Stock in respect of this Award.

6.                  
Date of Issuance. In the event that one or more RSUs vests, the Company will
issue to you one share of Common Stock for each vested RSU on the Settlement Date determined under the Grant Notice, but in all
cases not later than December 31 of the calendar year in which the Settlement Date occurs.

7.                  
Dividends. You will receive no benefit or adjustment to this Award with respect
to any cash dividend, stock dividend or other distribution except as provided in the Plan with respect to adjustments pursuant
to Sections 8.1 and 8.2.

8.                  
Restrictive Legends. The shares of Stock issued in respect of this Award will
be endorsed with appropriate legends, if any, as determined by the Company.

9.                  
Award not a Service Contract.

(a)               
Your continuous service with the Company or an Affiliate is not for any specified term and may be terminated by you or by the
Company or an Affiliate at any time, for any reason, with or without cause and with or without notice.  Nothing in this Agreement
(including, but not limited to, the vesting of your Award pursuant to the schedule set forth in Section 2 in this Agreement or
the issuance of the shares subject to your Award), the Plan or any covenant of good faith and fair dealing that may be found implicit
in this Agreement or the Plan will:  (i) confer upon you any right to continue in the employ of, or affiliation with, the
Company or an Affiliate; (ii) constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature
of future positions, future work assignments, future compensation or any other term or condition of employment or affiliation;
(iii) confer any right or benefit under this Agreement or the Plan unless such right or benefit has specifically accrued under
the terms of this Agreement or Plan; or (iv) deprive the Company or an Affiliate of the right to terminate you at will and without
regard to any future vesting opportunity that you may have.

(b)              
By accepting this Award, you acknowledge and agree that the right to continue vesting in the Award is earned only through continuous
service with the Company (not through the act of being hired, being granted this Award or any other award or benefit) and that
the Company has the right to reorganize, sell, spin-out or otherwise restructure one or more of its businesses or Affiliates at
any time or from time to time, as it deems appropriate (a “reorganization”).  You further acknowledge
and agree that such a reorganization could result in the termination of your continuous service with the Company, or the termination
of Affiliate status of your employer and the loss of benefits available to you under this Agreement, including but not limited
to, the termination of the right to continue vesting in the Award. You further acknowledge and agree that this Agreement, the Plan,
the transactions contemplated hereunder and the vesting schedule set forth in this Agreement or any covenant of good faith and
fair dealing that may be found implicit in any of them do not constitute an express or implied promise of continued engagement
as an employee, director or consultant for the term of this Agreement, for any period, or at all, and will not interfere in any
way with your right or the Company’s or an Affiliate’s right to terminate your continuous service with the Company
at any time, with or without cause and with or without notice.

    	 	2.	 

     

    

10.              
Withholding Obligations. On or before the time you receive a distribution of
the cash, shares or other property subject to your Award, or at any time thereafter as reasonably requested by the Company in compliance
with applicable law, you hereby authorize any required withholding from the Common Stock issuable to you and/or otherwise agree
to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax withholding obligations
of the Company or any Affiliate which arise in connection with your Award (the “Withholding Taxes”).
Without limiting the foregoing, the Company or an Affiliate, or their respective agents, may, in their sole discretion, satisfy
all or any portion of the Withholding Taxes obligation relating to your Award by any of the following means or by a combination
of such means: (i) withholding from any compensation otherwise payable to you by the Company; (ii) causing you to tender a cash
payment; (iii) permitting you to enter into a “same day sale” commitment with a broker-dealer that is a member of the
Financial Industry Regulatory Authority (a “FINRA Dealer”) whereby you irrevocably elect to sell a portion
of the shares to be delivered under the Award to satisfy the Withholding Taxes and whereby the FINRA Dealer irrevocably commits
to forward the proceeds necessary to satisfy the Withholding Taxes directly to the Company and/or its Affiliates, including a commitment
pursuant to a previously established Company-approved 10b5-1 plan, and/or (iv) if approved by the Committee in a manner that complies
with applicable laws, withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in
connection with the Award with a Fair Market Value (measured as of the date shares of Common Stock are issued to pursuant to Section
6) equal to the amount necessary to satisfy the Company’s required tax withholding obligations using the minimum statutory
withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to supplemental
taxable income. Unless the Withholding Taxes obligations of the Company and/or any Affiliate are satisfied, the Company will have
no obligation to deliver to you any Common Stock.

11.              
Tax Consequences. The Company has no duty or obligation to minimize the tax consequences
to you of this Award and will not be liable to you for any adverse tax consequences to you arising in connection with this Award.
You are hereby advised to consult with your own personal tax, financial and/or legal advisors regarding the tax consequences of
this Award and by accepting this Award, you have agreed that you have done so or knowingly and voluntarily declined to do so.

12.              
Unsecured Obligation. Your Award is unfunded, and as a holder of a vested Award,
you will be considered an unsecured creditor of the Company with respect to the Company’s obligation, if any, to issue shares
pursuant to this Agreement. You will not have voting or any other rights as a stockholder of the Company with respect to the shares
to be issued pursuant to this Agreement until such shares are issued to you. Upon such issuance, you will obtain full voting and
other rights as a stockholder of the Company. Nothing contained in this Agreement, and no action taken pursuant to its provisions,
will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other
person.

13.              
Other Documents. You hereby acknowledge
receipt or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities
Act, which includes the Plan prospectus. In addition, you acknowledge receipt of the Company’s policy permitting certain
individuals to sell shares only during certain “window” periods and the Company’s insider trading policy, in
effect from time to time and understand that this policy applies to shares received under this Award.

    	 	3.	 

     

    

14.              
Notices; Electronic Delivery. Any notices provided for in your Award or the Plan
will be given in writing and will be deemed effectively given upon receipt or, in the case of notices delivered by the Company
to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided
to the Company. Notwithstanding the foregoing, the Company may, in its sole discretion, decide to deliver any documents and transmit
or require you to transmit notices related to participation in the Plan and this Award by electronic means. You hereby consent
to receive such documents and notices, and to give such notices, by electronic delivery and to participate in the Plan through
the on-line or electronic system established and maintained by the Company or another third party designated by the Company from
time to time.

15.              
Miscellaneous.

(a)               
The rights and obligations of the Company under your Award will be transferable to any one or more persons or entities, and
all covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company’s successors and assigns.
Your rights and obligations under your Award may only be assigned with the prior written consent of the Company.

(b)              
You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of
the Company to carry out the purposes or intent of your Award.

(c)               
You acknowledge and agree that you have reviewed your Award in its entirety, have had an opportunity to obtain the advice of
counsel prior to executing and accepting your Award, and fully understand all provisions of your Award.

(d)              
This Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies
or national securities exchanges as may be required.

(e)               
All obligations of the Company under the Plan and this Agreement will be binding on any successor to the Company, whether the
existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially
all of the business and/or assets of the Company.

16.              
Governing Plan Document. This Award is subject to all the provisions of the Plan,
the provisions of which are hereby made a part of this Award, and is further subject to all interpretations, amendments, rules
and regulations which may from time to time be promulgated and adopted pursuant to the Plan. Except as otherwise expressly provided
in the Grant Notice or this Agreement, in the event of any conflict between the terms in the Grant Notice or this Agreement and
the terms of the Plan, the terms of the Plan will control. In addition, this Award (and any shares issued under this Award) is
subject to recoupment in accordance with the Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing
regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable
law.

17.              
Effect on Other Employee Benefit Plans. The value of this Award will not be included
as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan
sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its
rights to amend, modify, or terminate any of the Company’s or any Affiliate’s employee benefit plans.

    	 	4.	 

     

    

18.              
Stockholder Rights.  You will not have voting or any other rights as a stockholder
of the Company with respect to the shares of Stock to be issued pursuant to this Award until such shares are issued to you. Upon
such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this Agreement,
and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship
between you and the Company, any Affiliate or any other person.

19.              
Severability. If any part of this Agreement or the Plan is declared by any court
or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Agreement
or the Plan not declared to be unlawful or invalid. Any Section of this Agreement (or part of such a Section) so declared to be
unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of
a Section to the fullest extent possible while remaining lawful and valid.

20.              
Choice of Law. The interpretation, performance and enforcement of this Agreement
will be governed by the law of the state of Delaware without regard to such state’s conflicts of laws rules.

21.              
Amendment. This Agreement may not be modified, amended or terminated except by
an instrument in writing, signed by you and by a duly authorized representative of the Company. Notwithstanding the foregoing,
this Agreement may be amended solely by the Committee by a writing which specifically states that it is amending this Agreement,
so long as a copy of such amendment is delivered to you, and provided that no such amendment materially adversely affects your
rights hereunder may be made without your written consent. Without limiting the foregoing, the Committee reserves the right to
change, by written notice to you, the provisions of this Agreement in any way it may deem necessary or advisable to carry out the
purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial
decision, provided that any such change shall be applicable only to rights relating to that portion of the Award which is then
subject to restrictions as provided herein.

22.              
Compliance with Section 409A of the Code. This Award is intended to comply
with U.S. Treasury Regulation Section 1.409A-3(a) and will be construed and administered in such a manner, and any ambiguous or
missing terms that may otherwise be supplied from and/or defined under Code Section 409A in a manner that fulfills such intention
hereby incorporated by reference. Each installment of RSUs that vests hereunder is intended to constitute a “separate payment”
for purposes of Treasury Regulation Section 1.409A-2(b)(2). If you are a Specified Employee on your Separation from Service, then
the issuance of any shares, cash or other property that would otherwise be made on the date of your Separation from Service (or
within the first six months thereafter as a result of your Separation from Service) will not be made on the originally scheduled
date(s) and will instead be issued in a lump-sum on the earlier of (i) the date that is six months and one day after the date of
the Separation from Service or (ii) the date of your death, but if and only if such delay in the issuance is necessary to avoid
the imposition of taxation on you in respect of the shares, cash or property under Code Section 409A.

5.Exhibit 10.29

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

THIS EXECUTIVE EMPLOYMENT AGREEMENT (this
“Agreement”) is entered into by and between ArTara Therapeutics, Inc. (the “Company”), and
Julio Casoy, MD (“Executive”) (collectively referred to as the “Parties” or individually
referred to as a “Party”), effective as of February 13, 2020 (the “Effective Date”).

Whereas,
the Company and Executive desire to enter into this Agreement to define their mutual rights and duties with respect to Executive’s
compensation and benefits.

Now,
Therefore, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

1.                 
Duties and Scope of Employment.

(a)  
Positions and Duties. Executive will serve as Executive Vice President, Chief Medical Officer of the Company. Executive
will render such business and professional services in the performance of Executive’s duties, consistent with Executive's
position within the Company, as shall reasonably be assigned to Executive by the Company’s Chief Executive Officer. The period
of Executive’s at-will employment under the terms of this Agreement is referred to herein as the “Employment Term.”

(b)  
Obligations. During the Employment Term, Executive will perform Executive’s duties faithfully and to the best
of Executive’s ability and will devote Executive’s full business efforts and time to the Company. For the duration
of the Employment Term, Executive agrees not to actively engage in any other employment, occupation or consulting activity for
any direct or indirect remuneration without the prior approval of the Company’s Chief Executive Officer.

2.                 
At-Will Employment. Subject to Sections 7, 8, and 9 below, the parties agree that Executive's employment with the
Company will be “at-will” employment and may be terminated at any time with or without cause or notice, for any reason
or no reason. Executive understands and agrees that neither Executive’s job performance nor promotions, commendations, bonuses
or the like from the Company give rise to or in any way serve as the basis for modification, amendment, or extension, by implication
or otherwise, of Executive’s employment with the Company.

3.                 
Compensation.

(a)  
Base Salary. Effective as of January 10, 2020 and during the Employment Term the Company will pay Executive as compensation
for Executive’s services a base salary at a rate of $400,000 per year, as modified from time to time at the discretion of
the Board or a duly constituted committee of the Board (the “Base Salary”). The Base Salary will be paid in
regular installments in accordance with the Company’s normal payroll practices (subject to required withholding). Any increase
in Base Salary (together with the then existing Base Salary) shall serve as the “Base Salary” for future employment
under this Agreement. The first and last payment will be adjusted, if necessary, to reflect a commencement or termination date
other than the first or last working day of a pay period.

     

     

    

(b)  
Annual Bonus. Executive will also be eligible to earn an annual discretionary bonus with a target amount equal to
35% of Executive’s then current Base Salary. The amount of this bonus, if any, will be determined in the sole discretion
of the Board and based, in part, on Executive’s performance and the performance of the Company during the calendar year.
The bonus may be greater or lesser than the Target Bonus and may be zero based upon the achievement of agreed upon corporate and/or
individual goals. The Company will pay Executive this bonus, if any, on or about February 1st of the following calendar
year. The bonus is not earned until paid and no pro-rated amount will be paid if Executive’s employment terminates for any
reason prior to the payment date except as specified in Sections 7, 8 and 9.

(c)  
Equity. All Company equity awards previously granted to Executive shall continue in effect from and following the
Effective Date in accordance with their existing terms. Executive will be eligible to receive awards of stock options, restricted
stock or other equity awards pursuant to any plans or arrangements the Company may have in effect from time to time. The Board
or a committee of the Board shall determine in its discretion and guided by market benchmarks whether Executive shall be granted
any such equity awards and the terms of any such award in accordance with the terms of any applicable plan or arrangement that
may be in effect from time to time.

4.                 
Employee Benefits. During the Employment Term, Executive will be eligible to participate in the employee benefit
plans currently and hereafter maintained by the Company of general applicability to other senior executives of the Company, including,
without limitation, the Company’s group medical, dental, vision, disability, life insurance, and flexible-spending account
plans. The Company reserves the right to cancel or change the benefit plans and programs it offers to its employees at any time.

5.               
Business Expenses. During the Employment Term, the Company will reimburse Executive for reasonable business travel,
entertainment or other business expenses incurred by Executive in the furtherance of or in connection with the performance of Executive’s
duties hereunder, in accordance with the Company’s expense reimbursement policy as in effect from time to time.

6.                 
Termination on Death or Disability.

(a)  
Effectiveness. Executive’s employment will terminate automatically upon Executive’s Death or, upon fourteen
(14) days prior written notice from the Company, in the event of Disability.

(b)  
Effect of Termination. Upon any termination for death or Disability, Executive or his or her dependents shall be
entitled to: (i) Executive’s Base Salary through the effective date of termination; (ii) the right to continue health care
benefits under Title X of the Consolidated Budget Reconciliation Act of 1985, as amended (“COBRA”), at
the Company’s expense for a period of six (6) months, to the extent required and available by law; (iii) reimbursement of
expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet
been reimbursed; and (iv) no other severance or benefits of any kind, unless required by law or pursuant to any other written Company
plans or policies, as then in effect.

7.                 
Involuntary Termination for Cause; Resignation Without Good Reason.

 

(a)   Effectiveness.
Notwithstanding any other provision of this Agreement, the Company may terminate Executive’s employment at any time for Cause
or Executive may resign from Executive’s employment with the Company at any time without Good Reason. Termination for Cause,
or Executive’s resignation without Good Reason, shall be effective on the date either Party gives notice to the other Party
of such termination in accordance with this Agreement unless otherwise agreed by the Parties. In the event that the Company accelerates
the effective date of a resignation, such acceleration shall not be construed as a termination of Executives employment by the
Company or deemed Good Reason for such resignation.

 

    	 	-2-	 

     

    

(b)   Effect
of Termination. In the case of the Company’s termination of Executive’s employment for Cause, or Executive’s
resignation without Good Reason, Executive shall be entitled to receive: (i) Base Salary through the effective date of the termination
or resignation, as applicable; (ii) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant
to Section 5 above, but for which Executive has not yet been reimbursed; (iii) the right to continue health care benefits under
COBRA, at Executive’s cost, to the extent required and available by law; and (iv) no other severance or benefits of any kind,
unless required by law or pursuant to any other written Company plans or policies, as then in effect.

8.                 
Involuntary Termination Without Cause; Resignation for Good Reason.

(a)  
Effect of Termination. The Company shall be entitled to terminate Executive with or without Cause at any time, subject
to the following:

(i)           
If Executive is terminated by the Company involuntarily without Cause (excluding any termination due to death or Disability)
for Executive resigns for Good Reason, then, subject to the limitations of Sections 8(b) and 25 below, Executive shall be entitled
to receive: (A) Executive’s Base Salary through the effective date of the termination or resignation; (B) a lump sum severance
pay equal to nine (9) months of Executive’s Base Salary; (C) a lump sum payment equal to nine (9) months of Executive’s
bonus at target; (D) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section
5 above, but for which Executive has not yet been reimbursed; (E) reimbursement of any premium costs paid by Executive for the
same level of coverage Executive had during employment for nine (9) months; (F) pro-rata vesting of any outstanding equity awards
to the extent that Executive is not employed through the one-year anniversary of the applicable grant date of such outstanding
equity awards; (G) any unused and accrued vacation and (H) no other severance or benefits of any kind, unless required by law or
pursuant to any written Company plans or policies, as then in effect.

(b)  
Conditions Precedent. Any severance payments contemplated by Section 8(a) above are conditional on Executive:
(i) continuing to comply with the terms of this Agreement and the Confidential Information Agreement; and (ii) signing and not
revoking a separation agreement and release of known and unknown claims in the form provided by the Company (including nondisparagement
and no cooperation provisions) (the “Release”) and provided that such Release becomes effective and irrevocable
no later than sixty (60) days following the termination date or such earlier date required by the release (such deadline, the “Release
Deadline”). If the Release does not become effective by the Release Deadline, Executive will forfeit any rights to severance
or benefits under this Section 8 or elsewhere in this Agreement. Any severance payments or other benefits under this Agreement
that would be considered Deferred Compensation Separation Benefits (as defined in Section 25) will be paid on, or, in the case
of installments, will not commence until, the sixtieth (60th) day following Executive’s separation from service, or, if later,
such time as required by Section 25(b). Except as required by Section 25(b), any installment payments that would have been made
to Employee during the sixty (60) day period immediately following Executive’s separation from service but for the preceding
sentence will be paid to Executive on the sixtieth (60th) day following Executive’s separation from service and the remaining
payments will be made as provided in this Agreement, unless subject to the 6-month payment delay described herein. Any severance
payments under this Agreement that would not be considered Deferred Compensation Separation Benefits will be paid on, or, in the
case of installments, will not commence until, the first payroll date that occurs on or after the date the Release becomes effective
and any installment payments that would have been made to Executive during the period prior to the date the Release becomes effective
following Executive’s separation from service but for the preceding sentence will be paid to Executive on the first payroll
date that occurs on or after the date the Release becomes effective. Notwithstanding the foregoing, this Section 8(b) shall not
limit Executive’s ability to obtain expense reimbursements under Section 5 or any other compensation or benefits otherwise
required by law or in accordance with written Company plans or policies, as then in effect.

9.                 
Definitions.

    	 	-3-	 

     

    

(a)  
Cause. For purposes of this Agreement, “Cause” shall mean: (i) Executive’s willful and continued
failure to substantially perform the material duties and obligations under this Agreement (for reasons other than death or Disability),
which failure, if curable within the discretion of the Company, is not cured to the reasonable satisfaction of the Company within
thirty (30) days after receipt of written notice from the Company of such failure; (ii) Executive’s failure or refusal to
comply with the policies, standards and regulations established by the Company from time to time which results in a material loss,
damage or injury directly to the Company, and if curable in the discretion of the Company, is not cured to the reasonable satisfaction
of the Company within thirty (30) days after receipt of written notice of such failure from the Company; (iii) any act of personal
dishonesty, fraud, embezzlement, misrepresentation, or other unlawful act committed by Executive that benefits Executive at the
expense of the Company; (iv) the Executive’s violation of a federal or state law or regulation applicable to the Company’s
business; (v) the Executive’s violation of, or a plea of nolo contendre or guilty to, a felony under the laws of the
United States or any state; or (vi) the Executive’s material breach of the terms of this Agreement or the Confidential Information
Agreement (defined below).

(b)  
Change in Control. For purposes of this Agreement, “Change in Control” shall have the meaning attributed
to such term in the Proteon Therapeutics, Inc. Amended and Restated 2014 Equity Incentive
Plan or any successor plan of the Company (the "Option Plan") but shall not include the merger transaction
pursuant to that certain Agreement and Plan of Merger and Reorganization, dated September 23, 2019, by and among the Company, ArTara
Subsidiary, Inc. (formerly ArTara Therapeutics, Inc.) and REM 1 Acquisition, Inc.

(c)  
Disability. For purposes of this Agreement, “Disability” means that Executive, at the time notice
is given, has been unable to substantially perform Executive’s duties under this Agreement for not less than one-hundred
and twenty (120) work days within a twelve (12) consecutive month period as a result of Executive’s incapacity due to a physical
or mental condition and, if reasonable accommodation is required by law, after any reasonable accommodation.

(d)  
Good Reason. For purposes of this Agreement, “Good Reason” means Executive’s written notice
of Executive’s intent to resign for Good Reason with a reasonable description of the grounds therefor within 10 days after
the occurrence of one or more of the following without Executive’s consent, and subsequent resignation within 30 days following
the expiration of any Company cure period (discussed below): (i) a material diminution of Executive’s duties, position or
responsibilities; (ii) a material diminution in Executive’s Base Salary (other than a reduction of not more than 10% that
is applicable to similarly situated executives of the Company); (iii) any other action or inaction that constitutes a material
breach of this Agreement by the Company; or (iv) a material change in the geographic location of Executive’s primary work
facility or location; provided, that a relocation of less than 50 miles from Executive’s then present location will not be
considered a material change in geographic location. Executive will not resign for Good Reason without first providing the Company
with written notice of the acts or omissions constituting the grounds for “Good Reason” within 30 days of the initial
existence of the grounds for “Good Reason” and a reasonable cure period of not less than 30 days following the date
of such notice if such act or omission is capable of cure.

10.             
Acceleration of Options; Change in Control. If within eighteen (18) months following a Change in Control (as defined
above) the Company or the successor corporation terminates Executive’s employment with the Company or successor corporation
for other than Cause, death or Disability, then Executive shall be entitled to acceleration of 100% of Executive’s then-unvested
and outstanding equity awards.

11.             
 Company Matters.

(a)  
Proprietary Information and Inventions. In connection with Executive’s employment with the Company, Executive
will receive and have access to Company confidential information and trade secrets. Accordingly, enclosed with this Agreement is
an Employee Confidential Information and Inventions Assignment Agreement (the “Confidential Information Agreement”)
which contains restrictive covenants and prohibits unauthorized use or disclosure of the Company’s confidential information
and trade secrets, among other obligations. Executive agrees to review the Confidential Information Agreement and only sign it
after careful consideration.

    	 	-4-	 

     

    

(b)  
Resignation on Termination. On termination of Executive’s employment, regardless of the reason for such termination,
Executive shall immediately (and with contemporaneous effect) resign any directorships, offices or other positions that Executive
may hold in the Company or any affiliate, unless otherwise agreed in writing by the Parties.

(c)  
Notification of New Employer. In the event that Executive leaves the employ of the Company, Executive grants consent
to notification by the Company to Executive’s new employer about Executive’s rights and obligations under this Agreement
and the Confidential Information Agreement.

12.             
Arbitration. To ensure the timely and economical resolution of disputes that may arise in connection with Executive’s
employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action arising from
or relating to the enforcement, breach, performance, negotiation, execution, or interpretation of this Agreement, Confidential
Information Agreement, or Executive’s employment, or the termination of Executive’s employment, including but not limited
to all statutory claims, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent
permitted by law, by final, binding and confidential arbitration by a single arbitrator conducted in New York, New York
by Judicial Arbitration and Mediation Services Inc. (“JAMS”) under the then applicable JAMS rules (at
the following web address: https://www.jamsadr.com/rules-employment-arbitration/); provided, however, this arbitration provision
shall not apply to sexual harassment claims to the extent prohibited by applicable law. A hard copy of the rules will be provided
to Executive upon request. A hard copy of the rules will be provided to Executive upon request.  By agreeing to this arbitration
procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative
proceeding.  In addition, all claims, disputes, or causes of action under this Section, whether by Executive or the Company,
must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported
class or representative proceeding, nor joined or consolidated with the claims of any other person or entity.  The Arbitrator
may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class
proceeding.  To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable
law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law
rather than by arbitration.  The Company acknowledges that Executive will have the right to be represented by legal counsel
at any arbitration proceeding.  Questions of whether a claim is subject to arbitration under this Agreement) shall be decided
by the arbitrator.  Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also
matters for the arbitrator.  The arbitrator shall:  (a) have the authority to compel adequate discovery for the resolution
of the dispute and to award such relief as would otherwise be permitted by law; (b) issue a written arbitration decision, to include
the arbitrator’s essential findings and conclusions and a statement of the award; and (c) be authorized to award any or all
remedies that Executive or the Company would be entitled to seek in a court of law.  Executive and the Company shall equally
share all JAMS’ arbitration fees.  Except as modified in the Confidential Information Agreement, each party is responsible
for its own attorneys’ fees.  Nothing in this Agreement is intended to prevent either Executive or the Company from
obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  Any awards
or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.
To the extent applicable law prohibits mandatory arbitration of sexual harassment claims, in the event Executive intend to bring
multiple claims, including a sexual harassment claim, the sexual harassment may be publicly filed with a court, while any other
claims will remain subject to mandatory arbitration.

    	 	-5-	 

     

    

13.             
Assignment. This Agreement will be binding upon and inure to the benefit of (a) the heirs, executors and legal
representatives of Executive upon Executive's death and (b) any successor of the Company. Any such successor of the Company
will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, “successor”
means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly
or indirectly acquires all or substantially all of the assets or business of the Company. None of the rights of Executive to receive
any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent
and distribution. Any other attempted assignment, transfer, conveyance or other disposition of Executive’s right to compensation
or other benefits will be null and void.

14.             
Notices. All notices, requests, demands and other communications called for under this Agreement shall be in writing
and shall be delivered via e-mail, personally by hand or by courier, mailed by United States first-class mail, postage prepaid,
or sent by facsimile directed to the Party to be notified at the address or facsimile number indicated for such Party on the signature
page to this Agreement, or at such other address or facsimile number as such Party may designate by ten (10) days’ advance
written notice to the other Parties hereto. All such notices and other communications shall be deemed given upon personal delivery,
three (3) days after the date of mailing, or upon confirmation of facsimile transfer or e-mail. Notices sent via e-mail under this
Section shall be sent to either the e-mail address in this Agreement, or for e-mails sent by the Company to Executive, to the last
e-mail address on file with the Company.

15.             
Severability. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction
to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision.

16.             
Integration. This Agreement, together with the Option Plan and the Confidential Information Agreement represents
the entire agreement and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous
agreements whether written or oral. No waiver, alteration, or modification of any of the provisions of this Agreement will be binding
unless in writing and signed by duly authorized representatives of the parties hereto.

17.             
Tax Withholding. All payments made pursuant to this Agreement will be subject to withholding of applicable taxes.

18.             
Waiver. No Party shall be deemed to have waived any right, power or privilege under this Agreement or any provisions
hereof unless such waiver shall have been duly executed in writing and acknowledged by the Party to be charged with such waiver.
The failure of any Party at any time to insist on performance of any of the provisions of this Agreement shall in no way be construed
to be a waiver of such provisions, nor in any way to affect the validity of this Agreement or any part hereof. No waiver of any
breach of this Agreement shall be held to be a waiver of any other subsequent breach

19.             
Governing Law. This Agreement will be governed by the laws of the State of New York (with the exception of its conflict
of laws provisions).

20.             
Acknowledgment. Executive acknowledges that Executive has had the opportunity to discuss this matter with and obtain
advice from Executive’s legal counsel, has had sufficient time to, and has carefully read and fully understands all the provisions
of this Agreement, and is knowingly and voluntarily entering into this Agreement.

21.             
Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original,
and all such counterparts shall constitute but one instrument.

    	 	-6-	 

     

    

22.             
Effect of Headings. The section and subsection headings contained herein are for convenience only and shall not affect
the construction hereof.

23.             
Construction of Agreement. This Agreement has been negotiated by the respective Parties, and the language shall not
be construed for or against either Party.

24.             
Parachute Payments.If any payment or benefit Executive would receive from the Company or otherwise in connection
with a Change in Control or other similar transaction (a “280G Payment”) would (i) constitute a "parachute
payment" within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed
by Section 4999 of the Code (the “Excise Tax”), then any such 280G Payment (a "Payment") shall
be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment
that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up
to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after
taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at
the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater economic benefit
notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required
pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction
shall occur in the manner (the “Reduction Method”) that results in the greatest economic benefit for Executive.
If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the
“Pro Rata Reduction Method”). Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction
Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise
be subject to taxes pursuant to Section 409A of the Code, then the Reduction Method and/or the Pro Rata Reduction Method, as the
case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows: (A) as a
first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as
determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated
without cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority,
Payments that are “deferred compensation” within the meaning of Section 409A of the Code shall be reduced (or eliminated)
before Payments that are not deferred compensation within the meaning of Section 409A of the Code.

(a)  
Unless Executive and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for
general tax compliance purposes as of the day prior to the effective date of the Change in Control transaction triggering the Payment
shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor
for the individual, entity or group effecting the Change in Control transaction, the Company shall appoint a nationally recognized
accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations
by such accounting firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting
firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation,
to Executive and the Company within 15 calendar days after the date on which Executive’s right to a 280G Payment becomes
reasonably likely to occur (if requested at that time by Executive or the Company) or such other time as requested by Executive
or the Company.

(b)  
If Executive receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph
of this Section and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise
Tax, Executive shall promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x)
of the first paragraph of this Section so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance
of doubt, if the Reduced Amount was determined pursuant to clause (y) in the first paragraph of this Section, Executive shall have
no obligation to return any portion of the Payment pursuant to the preceding sentence.

    	 	-7-	 

     

    

25.             
Section 409A.

(a)  
Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to Executive,
if any, pursuant to this Agreement, when considered together with any other severance payments or separation benefits that are
considered deferred compensation under Section 409A (together, the “Deferred Compensation Separation Benefits”)
will be paid or otherwise provided until Executive has a “separation from service” within the meaning of Section 409A.

(b)  
Notwithstanding anything to the contrary in this Agreement, if Executive is a “specified employee” within the
meaning of Section 409A at the time of Executive’s termination (other than due to death), then the Deferred Compensation
Separation Benefits that are payable within the first six (6) months following Executive’s separation from service, will
become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of
Executive’s separation from service. All subsequent Deferred Compensation Separation Benefits, if any, will be payable in
accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if
Executive dies following Executive’s separation from service, but prior to the six (6) month anniversary of the separation
from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively
practicable after the date of Executive’s death and all other Deferred Compensation Separation Benefits will be payable in
accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under this Agreement
is intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.

(c)  
Any amount paid under this Agreement that satisfies the requirements of the “short-term deferral” rule set forth
in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Compensation Separation Benefits for purposes
of clause (a) above.

(d)  
Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from service
pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute
Deferred Compensation Separation Benefits for purposes of clause (a) above. For purposes of this Agreement, “Section 409A
Limit” will mean the lesser of two (2) times: (i) Executive’s annualized compensation based upon the annual rate
of pay paid to Executive during the Executive’s taxable year preceding Executive’s taxable year of Executive’s
termination of employment as determined under Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service
guidance issued with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant
to Section 401(a)(17) of the Code for the year in which Executive’s employment is terminated.

(e)  
The foregoing provisions are intended to comply with the requirements of Section 409A so that none of the severance payments
and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein
will be interpreted to so comply. The Company and Executive agree to work together in good faith to consider amendments to this
Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional
tax or income recognition prior to actual payment to Executive under Section 409A.

 

[Remainder of page is intentionally blank;
Signature page follows]

 

 

 

    	 	-8-	 

     

    

IN WITNESS WHEREOF, each of the Parties has
executed this Agreement as of the day and year first above written.

 

“COMPANY”

ArTara Therapeutics, Inc.

By:/s/ Jesse Shefferman

Address:

1 Little West 12th Street

New York, NY 10014

Attn: Jesse Shefferman

Fax Number:__________

Email: jesse.shefferman@artaratx.com

“EXECUTIVE”

Julio Casoy, MD

/s/ Julio Casoy

Executive Name

Address:

3726 Liseter Gardens, 

Newtown Square, PA 19073 

Fax Number:____________

Email: julio.casoy@artaratx.com

 

Enclosures

Duplicate Executive Employment Agreement

Employee Confidential Information and Inventions Assignment Agreement

New York Wage Notice Form (LS 59)

New York City Pregnancy Notice

New York City Earned Safe and Sick Time Act – Notice of Rights

New York City Notice Regarding Sexual Harassment

 

 

 

 

 

 

ArTara Therapeutics, Inc.

EXECUTIVE EMPLOYMENT AGREEMENT

SIGNATURE PAGE

 

 

-9-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]